Welcome to DailyUpdates Infectious diseases - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Infectious diseases



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

Previous Journal Entries

No previous journal articles today

Today's News Items

CONTRAVIR REPORTS POSITIVE DATA FROM PHASE 1B STUDY OF CMX157; HEAD-TO-HEAD PHASE 2A STUDY VS. VIREAD® ONGOING IN HEPATITIS B PATIENTS

Training Courses & Meetings

No events listed

Previous News Items

Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee

AstraZeneca’s antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation

European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C